Coya Therapeutics to Participate in BTIG Fireside Discussion

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Dr. Stanley Appel, M.D., Chairman of Coya’s Scientific Advisory Board and Chief Medical Officer Dr. Fred Grossman will participate in a fireside discussion with BTIG analyst Tom Shrader on Wednesday, March 13, 2024, at 12pm ET. Topics to be discussed include the role of regulatory T cells ...